John Livingstone

I'll research this attorney's background and the tracked case.

Let me verify the specific tracked case and any details on his role in it.

Let me check for a district court action between Bicara and Johns Hopkins, which is the tracked case.

Summary — John D. Livingstone (Finnegan, Henderson, Farabow, Garrett & Dunner)

Specialty / focus. Livingstone is a first-chair patent litigator whose practice centers on complex pharmaceutical, chemical, and biotechnology disputes before U.S. district courts, the ITC, and the Federal Circuit, with particular depth in Hatch-Waxman/ANDA litigation for innovator drug companies. His Finnegan profile and firm announcements confirm this focus on life-sciences and chemical matters; the tracked case (Bicara Therapeutics v. Johns Hopkins University, where he appeared as counsel for defendant Johns Hopkins) falls squarely within that biotech/pharma lane, involving Johns Hopkins patents on EGFR/TGFβ bifunctional antibody-ligand fusion proteins — technology at the center of the related Y-Trap v. Biocon/Bicara dispute over Bicara's lead candidate ficerafusp alfa (BCA101). Public PTAB records for the parallel PGR2026-00025 currently list DLA Piper as JHU's lead post-grant counsel, so the exact scope of his Finnegan-side role in the broader Bicara/JHU matter should be confirmed against the docket.

Side preference. Livingstone works almost exclusively on the defense/patent-owner side. His sole tracked appearance is a defendant-side representation, and his published case history is uniformly for innovator pharmaceutical and life-sciences patent owners (AstraZeneca, Novartis, Shionogi, Kissei, Allergan, Kaken, Bausch Health, Ajinomoto, Aventis) defending against generic ANDA challengers and IPR petitioners. No NPE/PAE enforcement work appears in his record.

Firm context and notable outcomes. He is a partner at Finnegan, Henderson, Farabow, Garrett & Dunner, based in Atlanta; he previously was resident in Finnegan's Tokyo office and served as managing partner of the firm's Atlanta office, and currently sits on its Management Committee. Noteworthy results include the Federal Circuit appellate victory in Kaken Pharmaceutical; Bausch Health v. Iancu (Jublia®/efinaconazole IPR appeal) and the district court win in AstraZeneca v. Aurobindo (Farxiga®) — both named LMG Life Sciences Impact Cases of the Year — plus trial and IPR wins for AstraZeneca/Shionogi on Crestor®, Onglyza®, and Kombiglyze® XR; district court litigation for Novartis on Kisqali®; and the Zolgensma® gene-therapy matter against Genzyme, which settled after multiple IPR institutions and claim-construction rulings. He has extensive PTAB/IPR experience, regularly serving as lead counsel in IPR and PGR proceedings (e.g., IPR2017-00190/-01429, IPR2015-01340, IPR2017-01551/-01698).

Bar / education. Admitted in Georgia (2001), registered to practice before the USPTO (2006), and admitted to the Federal Circuit (2005) and U.S. Supreme Court (2020); J.D. with honors from Emory University School of Law (2001, Order of the Coif), with M.S. (neuroscience) and B.S. (biochemistry) degrees from Florida State University.